OverviewChartNewsTraderScreen

BVT Bonus Zert AMD 28.03.2025/  DE000VM96FC9  /

Frankfurt Zert./VONT
14/05/2024  13:44:59 Chg.-1.600 Bid16:19:13 Ask16:19:13 Underlying Strike price Expiration date Option type
140.330EUR -1.13% 141.510
Bid Size: 7,300		 141.560
Ask Size: 7,300		 Advanced Micro Devic... - USD 28/03/2025 Call
GlobeNewswire 15:00 BOXX AI Workstations Bring AI to the Deskside and the Data Center
GlobeNewswire 14:00 Apellis Pharmaceuticals Refinances Existing Debt with Up to $475 Million Non-Dilutive Credit Facilit...
GlobeNewswire 14:00 Belite Bio to Participate in the Benchmark’s 4th Annual Healthcare House Call Investor Conference
GlobeNewswire 03:50 Belite Bio Reports First-Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire 13/05 Outlook Therapeutics® Announces UK Submission of Marketing Authorization Application (MAA) for ONS-5...
GlobeNewswire 13/05 AMD Remains the Partner of Choice for World’s Fastest and Most Efficient High Performance Computing ...
GlobeNewswire 09/05 Clearside Biomedical Announces First Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire 09/05 Adverum Biotechnologies Reports First Quarter 2024 Financial Results and Provides Pipeline Highlight...
GlobeNewswire 09/05 4DMT Reports First Quarter 2024 Financial Results and Operational Highlights
GlobeNewswire 08/05 Alkeus Pharmaceuticals Announces Positive Interim Results Demonstrating No Signs of Disease Progress...
GlobeNewswire 08/05 Therini Bio Announces Positive Preclinical Data Supporting the Development of THN391 in Neurodegener...
GlobeNewswire 08/05 AMD Receives IEEE 2024 Corporate Innovation Award for Leadership in Chiplet Design for High-Performa...
GlobeNewswire 08/05 Belite Bio to Host Webcast on May 14, 2024, to Discuss First Quarter 2024 Financial Results
GlobeNewswire 08/05 EyePoint Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Corporat...
GlobeNewswire 07/05 Ocular Therapeutix™ Reports First Quarter 2024 Results
GlobeNewswire 07/05 Optiver Chooses AMD Enterprise Portfolio to Power its Data Center Modernization, Enabling New Era of...
GlobeNewswire 07/05 Apellis Pharmaceuticals Reports First Quarter 2024 Financial Results
GlobeNewswire 07/05 Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire 06/05 Important Advances in Oxurion's R&D Program on Geographic Atrophy secondary to AMD
GlobeNewswire 06/05 Belite Bio to Participate in Key Opinion Leader Webinar to Discuss Unmet Needs In Stargardt Disease ...
GlobeNewswire 06/05 Belite Bio Presents Additional Analysis from Phase 2 Study of Tinlarebant in Stargardt Disease at th...
GlobeNewswire 06/05 Ocular Therapeutix™ to Present at Two Upcoming Investor Conferences
GlobeNewswire 06/05 EyePoint Pharmaceuticals Announces Topline Data from the Phase 2 PAVIA Trial of DURAVYU™ in Non-Prol...
GlobeNewswire 03/05 Ocular Therapeutix™ To Present at Two Ophthalmology Meetings, May 4-9, 2024
GlobeNewswire 03/05 YieldMax™ ETFs Announces Monthly Distributions on CONY (109.51%), MSTY (103.22%), NFLY (67.74%), SQY...